<DOC>
	<DOCNO>NCT00472199</DOCNO>
	<brief_summary>The primary objective current study evaluation long-term efficacy 26-weeks treatment pramipexole patient idiopathic moderate severe Restless Legs Syndrome ( RLS ) comparison placebo . The key secondary objective assess effect clinical global impression - global improvement ( CGI-I ) ( base CGI-I responder rate ) RLS ( base IRLS responder rate ) 26 week pramipexole comparison placebo . Further secondary objective investigate incidence severity augmentation rebound assess effect patient global impression ( PGI ) ( base PGI responder rate ) , RLS symptom ( base RLS-6 scale ) , associate mood disturbance ( base item 10 IRLS ) , pain limb ( base visual analogue scale ( VAS ) ) , quality life RLS ( base Johns Hopkins RLS-QoL ) , general quality life Short Form 36 ( SF-36 ) safety ( base adverse event ( AE ) profile ) pramipexole comparison placebo .</brief_summary>
	<brief_title>Long-term Efficacy , Safety Tolerability Pramipexole Patients With Idiopathic Moderate Severe Restless Legs Syndrome ( RLS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>1 . Written inform consent consistent International Conference Harmonization Good Clinical Practice ( ICHGCP ) local Institutional Review Board/Independent Ethics Committee ( IRB/IEC ) requirement obtain prior study procedure perform ability willingness comply study treatment regimen attend study assessment 2 . Male female outpatient age 1885 year 3 . Diagnosis idiopathic RLS accord clinical RLS criterion International Restless Legs Syndrome Study Group ( IRLSSG ) [ P0303355 ] . All four criterion must present fulfil diagnosis RLS . 4 . RLS symptoms present least 2 3 day per week last 3 month prior baseline ( Visit 2 ) 5 . IRLS total score &gt; 15 baseline ( Visit 2 ) 1 . Women childbearing potential ( i.e . premenopausal woman , postmenopausal woman le 6 month last menses ) use clinical trial adequate method contraception : double barrier protection ( e.g . diaphragm condom spermicide ) , intrauterine device , hormonal therapy ( oral , injectable , subcutaneous ) , partner 's surgical sterilization 2 . Any woman childbearing potential negative pregnancy test screen 3 . Breastfeeding woman 4 . Patients know hypersensitivity pramipexole component investigational product placebo tablets 5 . Diagnosis augmentation previous pharmacological RLS treatment 6 . Concomitant previous pharmacologic therapy follow : Any intake dopamine agonist within 14 day prior baseline ( Visit 2 ) ; Any intake levodopa within 14 day prior baseline ( Visit 2 ) ; Unsuccessful prior treatment nonergot dopamine agonist ( e.g . pramipexole , ropinirole ) ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>